Twitter Beğeni Hilesi

Trop-2 normalized membrane ratio (NMR), measured by quantitative continuous scoring (QCS) in TROPION-Lung01 Improved ORR & PFS in Trop-2 QCS-NMR positive vs. Trop-2 QCS-NMR negative groups, both in overall biomarker-evaluable population and in NSQ/non-AGA patients. #WCLC24

We had the pleasure to speak with Letícia Nogueira of American Cancer Society & Felipe Roitberg on the impact of climate change on #lungcaner risk at #WCLC24 🫁 Keep an eye out on our website over the next few days to see their discussion and the other updates! IASLC #LCSM #NSCLC #SCLC

Overcoming Osimertinib single agent in EGFR mut+ at #WCLC24 #LCSM OncoAlert

Learnings from VA system on successful implementation of #lungcancer screening. #WCLC24 ⁦IASLC⁩

At #WCLC24, we had the chance to catch up with Alex Spira, M.D. on: ⭐ valemetostat + datopotamab deruxtecan in pretreated #NSCLC ⭐ MARIPOSA ⭐ METalmark See his interview and other #lungcancer updates at VJOncology.com! IASLC #LCSM

NADIM 5Y survival analysis, by Grupo Español de Cáncer de Pulmón M.Provencio . Sustained long-term benefit for Periop ChIO, reaching a plateau for disease prog (5y PFS of 65%). PD-L1 and TMB biomarkers alone are not good enough, need for more translational research.IASLC #wclc24

🫁 Day 3 of #WCLC24 is underway! Discover the latest in #lungcancer therapies and follow VJ Oncology or visit VJOncology.com for updates. IASLC #LCSM #NSCLC #SCLC

Dr. Gerrina Ruiter presents an update on the Beamion LUNG-1 study: zongertinib in #HER2 mutant NSCLC at the #WCLC24 Presidential Plenary. Here, Phase Ib cohort 1: previously treated NSCLC with a #HER2 TKD mutation that set the dose of 120mg by mouth daily.

Dr Chee Lee discusses SOHO-01 & BEAMION-Lung01. Questions re how do these stack against T-DxD. Is BAY 20mg BID optimal schedule? Ph3 trials for both underway. #WCLC24

FURMO-002; Firmonertinib in EGFR PACC; )has a 78% Orr in ex20ins); cohort4 = PACC only; 30% BM; mDOR NR; icORR 55-46%; at higher dose level DR on over 20%; #WCLC24

POLESTAR: Aumolertinib consolidation following Sequential or concurrent CRT. Treatment till PD/ tox. N=147. 85% x-over from control arm. HR PFS 0.2 Control arm median 3.8mo(!). ORR 57 vs22%. 15% increase in RT pneumonitis Supports LAURA but control arm poor performance #WCLC24

1st phase III trial of an ADC vs docetaxel in a biomarker selected population Tusamitamab Ravtansine targets CEACAM5, overexpressed in 25% of non sq NSCLC CARMEN LC03 did not meet the primary endpoints PFS and OS. #WCLC24

At #WCLC24, we got to catch up with Gerry Hanna on multimodal approaches in stage III #NSCLC, going through the LAURA, SQUAT, APOLO, and PACIFIC-BRAZIL trials🫁 See all the #lungcancer highlights and more on VJOncology.com! IASLC #LCSM

APOLO Trial of induction chemo-IO followed by concurrent chemoRT and maintenance atezo a promising option for stage III NSCLC. 📖 Needs ph III to assess vs PACIFIC regimen. ⁉️How do we integrate this with perioperative regimens for resectable stage III? IASLC #WCLC24

🫁 Final day of #WCLC24! We hope you’re enjoying the event as much us in San Diego. Visit VJOncology.com for more updates in #lungcancer! IASLC VJ Oncology #LCSM #NSCLC #SCLC

It may be the last day of #WCLC24 in San Diego, but we're still having great conversations with #lungcancer experts! Hidehito HORINOUCHI speaks to us on #NSCLC trials including: ⭐Safety data from ALINA of alectinib ⭐Teliso-V in LUMINOSITY 🌸Osi ± savolitinib in FLOWERS IASLC #LCSM

So proud of my amazing mentor JessicaJLinMD for presenting updated efficacy, safety, & biomarker data for #larotrectinib for pts w/ NTRK-rearranged🫁cancer #WCLC24 💠IRC-ORR 66%, median PFS 22 mo, median OS 39 mo 💠Acquired resistance in 5 of 13 pts w/ post-progression biopsies

As #WCLC24 comes to a close, it was great to speak with gilberto lopes on the SKIPPirr trial, which aimed to reduce infusion-related AEs with intravenous amivantamab in #lungcancer See who else we've been talking to on VJOncology.com 🖥️ IASLC #LCSM #NSCLC #SCLC